Trial reportBMC complementary medicine and therapies2025
Efficacy and safety of Wuling capsule for the treatment of mild depression in patients with early Parkinson's disease in China: a randomized clinical trial.
Trial report in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
backgroundDepression is a prevalent non-motor symptom of Parkinson's disease (PD) that significantly impacts patients' quality of life. The Wuling capsule, a traditional Chinese medicine, is often utilized for treating depression, and this herbal medicine has been used to treat those PD patients with depression. This study aims to assess the efficacy and safety of Wuling capsule in treating mild depression in patients with early PD.
methodsThis multicenter, double-blind, placebo-controlled randomized clinical trial included 160 patients with early PD who presented with a Hamilton Rating Scale for Depression (HAMD) score between 8 and 17 at the time of admission. The trial was conducted across five hospitals in China from December 2021 to March 2024. Eligible patients were randomly assigned to receive either Wuling capsule (0.99 g orally three times daily) or a placebo (0.99 g orally three times daily) for a duration of 12 weeks. Additional treatment according to established clinical guidelines.The primary outcome measure was the change in HAMD score. All statistical analyses were conducted on an intention-to-treat population.
resultsAfter 12 weeks of treatment, among the 160 patients with early PD and depression, 80 were assigned to the Wuling capsule group and 80 to the placebo group, with the median age of 70.5 (IQR,67.00-75.00) years and 77 (48.13%) were male. Patients in the Wuling capsule group demonstrated significantly greater reductions in depression severity compared to the placebo group at multiple time points: week 4 (difference, - 1.21 [95% CI, -2.38 to -0.04; P = 0.042]), week 8 (difference, - 1.41 [95% CI, -2.81 to -0.02; P = 0.047]), and week 12 (difference, - 1.46 [95% CI, -2.89 to -0.04; P = 0.044]). Adverse events were reported in 3 of 80 patients (3.75%) in the Wuling capsule group and 3 of 80 patients (3.75%) in the control group (P = 1), indicating no significant difference.
conclusionThis randomized clinical trial demonstrated that treatment with Wuling capsule over a 12-week period effectively reduced HAMD score in patients with mild depression associated with PD and the treatment was well tolerated.
trial registrationChinese Clinical Trial Registry; registration number: ChiCTR2100046195; prospectively registered on May 9th, 2021.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.